About this Research Topic
Anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the treatment of neovascular and leaking retinal diseases. The current management involves frequent intravitreal injections, posing challenges such as the requirement for long-lasting or sustained-release formulations and addressing non-responder cases.
This research topic aims to document real-life experiences with new anti-VEGF therapies, focusing on the challenges faced by patients, healthcare systems, and clinicians. The chronic nature of neovascular age-related macular degeneration (nAMD) and other retinal vascular diseases, necessitates repeat injections, impacting patient compliance and visual outcomes. 'Poor responders' pose a unique challenge, indicating the need for alternative treatment targets beyond VEGF pathway inhibition.
Clinical trials have explored varying formulations, dosing regimens, and economic considerations, but real-life studies reveal discrepancies, emphasizing the importance of understanding practical implications. Emerging perspectives include drugs targeting multiple pathways, longer half-lives, and controlled-release devices, signalling a complex future for management of nAMD, proliferation diabetic retinopathy (PDR), diabetic macular edema (DME), macular edema secondary to retinal vein occlusions (RVO), etc.
The goal is to collect experiences with these innovations, providing insights into their real-world effectiveness, challenges, and potential advancements. This comprehensive approach aims to bridge the gap between controlled trials and everyday clinical scenarios, contributing valuable data to optimize the evolving landscape of anti-VEGF therapies in macular diseases.
This research topic aims to document real-life experiences with new anti-VEGF therapies, focusing on the challenges faced by patients, healthcare systems, and clinicians. The chronic nature of neovascular age-related macular degeneration (nAMD) and other retinal vascular diseases, necessitates repeat injections, impacting patient compliance and visual outcomes. 'Poor responders' pose a unique challenge, indicating the need for alternative treatment targets beyond VEGF pathway inhibition.
Clinical trials have explored varying formulations, dosing regimens, and economic considerations, but real-life studies reveal discrepancies, emphasizing the importance of understanding practical implications. Emerging perspectives include drugs targeting multiple pathways, longer half-lives, and controlled-release devices, signalling a complex future for management of nAMD, proliferation diabetic retinopathy (PDR), diabetic macular edema (DME), macular edema secondary to retinal vein occlusions (RVO), etc.
The goal is to collect experiences with these innovations, providing insights into their real-world effectiveness, challenges, and potential advancements. This comprehensive approach aims to bridge the gap between controlled trials and everyday clinical scenarios, contributing valuable data to optimize the evolving landscape of anti-VEGF therapies in macular diseases.
Keywords: Anti-VEGF therapies, neovascular retinal diseases, macular degeneration, diabetic retinopathy, intravitreal injections, sustained release formulations, treatment efficacy, healthcare economics, patient compliance
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
